Myriad Genetics Inc.

$28.31 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Join the waitlist

About Myriad Genetics Inc.

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Stock Analysis

last close $28.48
1-mo return 3.6%
3-mo return 17.8%
avg daily vol. 808.19T
52-week high 33.97
52-week low 10.54
market cap. $2.4B
forward pe -
annual div. -
roe -12.9%
ltg forecast -
dividend yield -
annual rev. $600M
inst own. -
baraka

Join the waitlist for early access and a chance to earn $50 in free stock

Join the waitlist